Management of advanced medullary thyroid cancer

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 1, 2016, Pages 64-71

  Hadoux, Julien ^a   Pacini, Furio ^b   Tuttle, R Michael ^c   Schlumberger, Martin ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF SIENA   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CABOZANTINIB; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DACARBAZINE; DENOSUMAB; DOXORUBICIN; FLUOROURACIL; GEFITINIB; IMATINIB; LENVATINIB; LEVOTHYROXINE; MOTESANIB; OCTREOTIDE; PAZOPANIB; SORAFENIB; SUNITINIB; VANDETANIB; ZOLEDRONIC ACID; ANILIDE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ABDOMINAL DISCOMFORT; ADVANCED CANCER; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CRYOABLATION; DECREASED APPETITE; DIARRHEA; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFICACY; FATIGUE; FOLLICULITIS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; THYROID MEDULLARY CARCINOMA; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NEUROENDOCRINE; DISEASE FREE SURVIVAL; THYROID NEOPLASMS; TREATMENT OUTCOME;

ANILIDES; ANTINEOPLASTIC AGENTS; BIOMARKERS; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NEUROENDOCRINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; PIPERIDINES; PYRIDINES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84955369333     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00337-X     Document Type: Review

References (70)

1. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015, 25:567-610. the American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma.
2. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008, 93:682-687.
3. Moura MM, Cavaco BM, Pinto AE, Leite V High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011, 96:E863-E868.
4. Boichard A, Croux L, Al Ghuzlan A, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 2012, 97:E2031-E2035.
5. Agrawal N, Jiao Y, Sausen M, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013, 98:E364-E369.
6. Bergholm U, Bergström R, Ekbom A Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997, 79:132-138.
7. Esfandiari NH, Hughes DT, Yin H, Banerjee M, Haymart MR The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 2014, 99:448-454.
8. Kebebew E, Ituarte PHG, Siperstein AE, Duh Q-Y, Clark OH Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000, 88:1139-1148.
9. Mehrotra PK, Mishra A, Mishra SK, Agarwal G, Agarwal A, Verma AK Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India. World J Surg 2011, 35:1273-1280.
10. Modigliani E, Cohen R, Campos J-M, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 1998, 48:265-273.
11. Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007, 33:493-497.
12. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984, 63:319-342.
13. Pazaitou-Panayiotou K, Chrisoulidou A, Mandanas S, Tziomalos K, Doumala E, Patakiouta F Predictive factors that influence the course of medullary thyroid carcinoma. Int J Clin Oncol 2014, 19:445-451.
14. Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008, 158:239-246.
15. Barbet J, Campion L, Kraeber-Bodéré F, Chatal J-F Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005, 90:6077-6084. the GTE Study Group.
16. Frank-Raue K, Machens A, Leidig-Bruckner G, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid 2013, 23:294-300.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
18. Machens A, Schneyer U, Holzhausen H-J, Dralle H Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005, 90:2029-2034.
19. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007, 92:4185-4190.
20. 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007, 48:501-507.
21. Kauhanen S, Schalin-Jäntti C, Seppänen M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med 2011, 52:1855-1863.
22. 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 2012, 53:1863-1871.
23. Akeno-Stuart N, Croyle M, Knauf JA, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007, 67:6956-6964.
24. Kurzrock R, Atkins J, Wheler J, et al. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol 2013, 24:2256-2261.
25. Postel-Vinay S, Schlumberger M, Soria J-C Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?. Ann Oncol 2013, 24:2201-2204.
26. Tsutsui H, Kubota M, Yamada M, et al. Airway stenting for the treatment of laryngotracheal stenosis secondary to thyroid cancer. Respirology 2008, 13:632-638.
27. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000, 85:983-988.
28. Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011, 96:2796-2804.
29. Baudry C, Paepegaey A-C, Groussin L Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med 2013, 369:584-586.
30. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012, 48:3082-3092.
31. Wang Z, Qiao D, Lu Y, et al. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Oncologist 2015, 20:440-449.
32. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D External radiotherapy in thyroid cancers. Cancer 1985, 55(suppl):2062-2071.
33. Bernad DM, Sperduto PW, Souhami L, Jensen AW, Roberge D Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neurooncol 2010, 98:249-252.
34. Fromigué J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:2496-2499.
35. Lorenz K, Brauckhoff M, Behrmann C, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 2005, 138:986-993.
36. de Baère T, Aupérin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015, 26:987-991.
37. Deschamps F, Farouil G, de Baere T Percutaneous ablation of bone tumors. Diagn Interv Imaging 2014, 95:659-663.
38. Mohan H, Nicholson P, Winter DC, et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 2015, 26:935-942.
39. Wertenbroek MW, Links TP, Prins TR, Plukker JTM, van der Jagt EJ, de Jong KP Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid 2008, 18:1105-1110.
40. Chougnet CN, Borget I, Leboulleux S, et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 2015, 25:386-391.
41. Iten F, Müller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007, 13:6696-6702.
42. Kraeber-Bodéré F, Goldenberg DM, Chatal JF, Barbet J Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. Curr Oncol 2009, 16:3-8.
43. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985, 56:2155-2160.
44. Williams SD, Birch R, Einhorn LH Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986, 70:405-407.
45. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer 2000, 83:715-718.
46. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 1995, 71:363-365.
47. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010, 20:863-871.
48. Papotti M, Olivero M, Volante M, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 2000, 11:19-30.
49. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28:767-772.
50. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010, 28:2323-2330.
51. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009, 27:3794-3801.
52. Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26:4708-4713.
53. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16:5260-5268.
54. Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). Clin Cancer Res 2015, published online Aug 26. 10.1158/1078-0432.CCR-15-1127.
55. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011, 29:2660-2666.
56. Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014, 99:1687-1693. the Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer CenterMayo Clinic Cancer Center, the Mayo Phase 2 Consortiumthe Mayo Phase 2 Consortium.
57. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18:317-323.
58. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007, 157:215-220.
59. de Groot JWB, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:3466-3469.
60. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30:134-141.
61. Schlumberger M, Elisei R, Müller SP, et al. Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. J Clin Oncol 2015, 33(suppl 5). abstr 6012.
62. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013, 31:3639-3646.
63. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95:2664-2671.
64. Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 2013, 19:4239-4248.
65. Sherman SI, Cohen EEW, Schoffski P, et al. Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: results from a phase III study. J Clin Oncol 2013, 31(suppl). abstr 6000.
66. Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 2012, 148:1418-1420.
67. Brassard M, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab 2011, 96:2741-2749.
68. Cabanillas ME, Hu MI, Jimenez C Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat-and with which drug-those are the questions. J Clin Endocrinol Metab 2014, 99:4390-4396.
69. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004, 23:6056-6063.
70. Hong DS, Cabanillas ME, Wheler J, et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 2011, 96:997-1005.